Summary: Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) usually shows an autosomal dominant inheritance pattern, with incomplete penetrance and variable clinical expression. Classically, index patients present between the second and fourth decades of life with right ventricular tachycardia. However, sudden death can occur at adolescence, whereas mutation carriers may remain without signs and symptoms until old age. Previous genotype-phenotype studies involved mainly overt index patients. Data on mainly asymptomatic relatives were scarce. To gain insight into the full spectrum of the disease, 149 ARVD/C index patients and 302 of their relatives were genotypically and phenotypically characterized. DNA analysis comprised sequencing of the desmosomal genes PKP2, DSC2, DSG2, DSP, and JUP and multiplex ligationdependent probe amplification to identify large deletions in PKP2. Pathogenic mutations were identified in 87 of 149 ARVD/C index patients (58%), mainly truncating PKP2 mutations with multiple mutations in 2% of cases. Performing multiplex ligation-dependent probe amplification also appeared to be important; its 2% mutational yield was comparable to the sequencing of DSG2 or DSC2. IdentiCorrespondence to The Editors, Circulation Editorial Office,
Genome-Wide Association Study for Coronary Artery Calcification With Follow-Up in Myocardial Infarction
Summary: Coronary artery calcification, detected by computed tomography, is a noninvasive measure of coronary atherosclerosis and an independent predictor of myocardial infarction. We conducted a genome-wide association study with a discovery sample of nearly 10 000 participants of European original and a replication sample of Ͼ6000 participants of European origin. We report strong evidence for genetic variants in 9p21 near the CDKN2B and CDKN2A genes and in 6p24 within the PHACTR1 gene. Additionally, we found evidence for concordance of single-nucleotide polymorphism associations with both coronary artery calcification and some but not all other loci known to be associated with myocardial infarction, including 3q22 (MRAS gene), 13q34 (COL4A1/COL4A2 genes), and 1p13 (SORT1 gene). These findings reinforce the important role of variation at multiple genes in the pathogenesis of coronary atherosclerosis. Although the functional mechanism of many of these genetic associations remains to be determined, our comprehensive study lays the groundwork for future studies to determine the role of several genes in treatment, prediction, and prevention of coronary atherosclerosis and resulting myocardial infarction and other clinically apparent forms of coronary heart disease.
Conclusions: SNPs in the 9p21 and PHACTR1 gene loci were strongly associated with coronary artery calcification and myocardial infarction, and there are suggestive associations with both coronary artery calcification and myocardial infarction of SNPs in additional loci. Multiple genetic loci are associated with development of both underlying coronary atherosclerosis and clinical events. 1 
Distinct Epigenomic Features in End-Stage Failing Human Hearts
Summary: Molecular research in heart failure points to the hypothesis that a generic cardiac genomic response is activated in the failing myocardium regardless of the original inciting cause. This cardiac genomic stress response is typified by the re-expression of fetal genes, upregulation of fibrosis-related genes, and others. It may also reflect unifying features of a failed myocardium such as fibrosis, altered energy use, vascular rarefaction, cell death, and altered contractility, all of which are features found in the failing myocardium again regardless of the inciting cause. The epigenome refers to "marks" on the genome, including DNA methylation and histone modification. The epigenome regulates the expression of underlying genes, and recent evidence suggests that part of the epigenome may be altered by diet and the environment. In our research, we have examined the genome-wide landscape of the epigenome of healthy and end-stage cardiomyopathic human hearts. We have determined that distinct epigenomic patterns exist in important DNA elements of the human cardiac genome in the failing myocardium. Individually, sites of differential epigenomic patterns may control the expression of specific genes with critical functions in the progression of heart failure. However whether the altered epigenome is simply a consequence in end-stage disease or actually contributes to disease progression remains to be determined. This work now opens an important new avenue of research because the epigenome may represent a drug discovery target for novel heart failure therapy.
Conclusions: Distinct epigenomic patterns exist in important DNA elements of the cardiac genome in human end-stage cardiomyopathy. The epigenome may control the expression of local or distal genes with critical functions in myocardial stress response. If epigenomic patterns track with disease progression, assays for the epigenome may be useful for assessing prognosis in heart failure. Further studies are needed to determine whether and how the epigenome contributes to the development of cardiomyopathy. 2 fication of mutations in index patients had major consequences for the concurrent relatives. Of the 57 of 282 initially asymptomatic relatives (20%) who showed any sign of ARVD/C, 84% carried a mutation. These 48 mutation carriers had earlier onset of disease signs and symptoms than noncarriers but also a markedly increased risk of arrhythmias and 6-fold risk of ARVD/C diagnosis. Familial cases were identified in 45% of families screened. Prolonged terminal activation duration seemed to be an early marker of ARVD/C; it was observed more often than negative T waves in V 1 to V 3 , especially in mutation-carrying relatives Ͻ20 years of age.
Conclusions: Pathogenic desmosomal gene mutations, mainly truncating PKP2 mutations, underlie ARVD/C in the majority (58%) of Dutch index patients and even 90% of familial cases. Additional multiplex ligation-dependent probe amplification analysis contributed to discovering pathogenic mutations underlying ARVD/C. Discovering pathogenic mutations in index patients enables those relatives who have a 6-fold increased risk of ARVD/C diagnosis to be identified. Prolonged terminal activation duration seems to be a first sign of ARVD/C in young asymptomatic relatives. 3 
Familial Evaluation in Arrhythmogenic Right Ventricular Cardiomyopathy: Impact of Genetics and Revised Task Force Criteria
Summary: Arrhythmogenic right ventricular cardiomyopathy is a genetically determined autosomal dominant cardiac disorder caused by mutations in desmosomal genes. Clinical presentation is typically with arrhythmia and/or sudden death during the second and third decades. This study confirms this perspective; 51 of 100 probands presented with sudden death, 14 between the ages of 14 and 20 years. The study also examined family members in whom the molecular genetic status was known. Disease expression in relatives was milder, developed later in life, and was associated with a low incidence of arrhythmia/sudden death. Relatives with multiple genetic variants, however, had more severe disease expression with sudden death. It is unclear whether multiple variants explain the early presentation with sudden death seen in Ͼ30% of probands, or whether later-onset disease is progressive with clinical arrhythmia complications developing in later decades. The findings of this study underscore the role of mutation analysis with cascade screening of families to enable appropriate genetic counseling and targeted serial cardiac evaluation.
Conclusions: Arrhythmogenic right ventricular cardiomyopathy is a genetically complex disease characterized by marked intrafamilial phenotype diversity. Penetrance is definition dependent and is greater with the 2010 criteria compared with the 1994 criteria. Relatives harboring Ͼ1 genetic variant had significantly increased risk of developing clinical disease, potentially an important determinant of the phenotypic heterogeneity seen within families with arrhythmogenic right ventricular cardiomyopathy. 4 
Renin-Angiotensin-Aldosterone Genotype Influences Ventricular Remodeling in Infants With Single Ventricle
Summary: The Pediatric Heart Network conducted a pharmacogenetic study as part of a multicenter randomized, controlled trial of enalapril versus placebo in single-ventricle infants to assess if renin-angiotensin-aldosterone system (RAAS)-upregulation genotypes influence the response to enalapril. This represents the first pharmacogenetic study of enalapril in a congenital heart disease population. One-hundred fifty-four infants with single ventricle were genotyped and followed up until 14 months of age. Patients with RAAS-upregulation genotypes had persistent increase in ventricular mass and volume despite volume-unloading surgery (ie, superior cavopulmonary connection). Enalapril did not decrease ventricular mass or volume in either genotype group. Patients with high-risk genotypes had lower weight and height at enrollment, and the height impairment persisted in high-risk patients who were receiving enalapril whereas patients receiving placebo normalized their height by 14 months. The high-risk genotype group also showed mild but persistent renal dysfunction. In summary, patients with RAAS-upregulation genotypes failed to show reverse remodeling in response to volumeunloading surgery, had persistent growth abnormalities, especially with enalapril, and had persistent renal dysfunction. These patients may need earlier superior cavopulmonary connection to facilitate reversal of ventricular dilation and hypertrophy before the remodeling becomes irreversible. Because neither enalapril nor surgery showed significant benefit in high-risk genotype patients, there is a need to develop newer therapies in at-risk patients.
Conclusions: Renin-angiotensin-aldosterone system-upregulation genotypes were associated with failure of reverse remodeling after superior cavopulmonary connection surgery, less improvement in renal function, and impaired somatic growth, the latter especially in patients receiving enalapril. Renin-angiotensin-aldosterone system genotype may identify a high-risk subgroup of single ventricle patients who fail to fully benefit from volume-unloading surgery. Follow-up is warranted to assess long-term impact. 5 
Genetic Predictors of Fibrin D-Dimer Levels in Healthy Adults
Summary: Activation of blood coagulation plays a key role in hemostasis and in arterial and venous thrombosis. Fibrin D-dimer is the most widely used clinical marker of activated blood coagulation. Epidemiological and clinical studies over the last 20 years have established its associations with risk of arterial and venous thromboembolic events and with other pathologies. This article reports a novel association of plasma D-dimer levels with variation upstream from F3, the gene for tissue factor. The manuscript also confirms a previous report that D-dimer levels are associated with the factor V Leiden F5 R506Q variant (rs6025) and the FGA Ala331Thr variant (rs6050) variant, which are also associated with risk of arterial and venous thrombosis. Our demonstration that a genetic variant upstream from F3 is associated with variation in D-dimer levels in generally healthy populations supports the concept that F3 might be a potential therapeutic target to reduce thrombotic risk.
Conclusions:
Three genes were associated with fibrin D-dimer levels. Of these 3, the F3 association was the strongest, and has not been previously reported. 6 
Transcriptomic Biomarkers for the Accurate Diagnosis of Myocarditis
Summary: New diagnostic tools based on gene signatures derived from the entire complement of messenger RNAs in a cell or tissue have become established in the clinical management of certain disorders, particularly cancer. The comprehensiveness of this approach contributes to its accuracy. Myocarditis is a disorder that causes a substantial proportion of patients presenting with new-onset heart failure and left ventricular dysfunction. Typically diagnosed by endomyocardial biopsy and evaluated with histological criteria called the Dallas criteria, clinical management is hampered by low sensitivity and specificity and the need for multiple cardiac biopsies. The present study suggests that the application of a transcriptomic based biomarker can substantially improve the diagnostic accuracy of heart biopsy for myocarditis. Using endomyocardial biopsy tissue obtained at the time of clinical presentation, we developed a molecular signature comprising 62 genes that predicted with high accuracy the presence of myocarditis in a population of 48 patients. Importantly, this required evaluation of tissue from a single endomyocardial biopsy sample and therefore is clinically practical. The present results could provide treating physicians with important and accurate diagnostic information about individual patients and could provide tools for personalized treatment or monitoring. Given emerging treatment strategies for viral and inflammatory myocarditis, accurate diagnostic tools are of increased importance.
Conclusions:
Together, these findings demonstrate that transcriptomic biomarkers from a single endomyocardial biopsy can improve the clinical detection of patients with inflammatory diseases of the heart. This approach advances the clinical management and treatment of cardiac disorders with highly variable outcome. 7 
Molecular Basis of Autosomal Dominant Hypercholesterolemia: Assessment in a Large Cohort of Hypercholesterolemic Children
Summary: Autosomal dominant hypercholesterolemia (ADH) is characterized by severely elevated low-density lipoprotein cholesterol levels from birth on, enhanced atherosclerosis progression, and premature cardiovascular events. Functional and morphological changes of the arterial wall are observed in children with ADH, which indicates that the atherosclerotic process has already been initiated. Early diagnosis and treatment of ADH are pivotal because therapy with lipid-lowering agents strongly decreases the risk for cardiovascular events. If possible, a clinical diagnosis of FH should preferably be confirmed by molecular genetic testing. Furthermore, the imprecision of any current clinical screening strategy for ADH emphasizes the relevance of genetic testing for definite diagnosis of ADH and screening purposes in affected families. This study shows that, if stringent criteria are used, a functional mutation can be found in 95% of children. We therefore feel that children are better suited for the definition of the molecular basis of a dyslipidemic phenotype. This knowledge can help clinicians establish the definite diagnosis of ADH in families. Once a child is identified as having ADH, cascade screening can be performed to screen more distant relatives using the inheritance pattern across the pedigree. Furthermore, these data strongly suggest that most of the large-effect genes underlying ADH have been found, at least in the Netherlands. This is of importance because any novel gene implicated in the pathogenesis of ADH and cardiovascular disease could become a pharmacological target in itself; hence, it is important to establish whether a large proportion of ADH patients still carry unexplained molecular defects.
Conclusion:
In the vast majority of children with an ADH phenotype, a causative mutation can be identified, strongly suggesting that most of the large-effect genes underlying ADH are known to date. 8
Meta-Analysis of Genome-Wide Association Studies in >80 000 Subjects Identifies Multiple Loci for C-Reactive Protein Levels
Summary: C-reactive protein (CRP) is a heritable marker of chronic inflammation that is strongly associated with cardiovascular disease. Although environmental factors such as obesity, smoking, and hormone therapy influence levels of serum CRP, genes play an important role in determining serum CRP levels. The advent of genome-wide association studies has provided an opportunity to identify previously unsuspected genetic loci that influence complex traits. In this study, we collected data on Ͼ80 000 subjects from 25 studies and identified 18 genetic loci that are associated with serum CRP levels. These genetic loci provide valuable insights into the pathways that affect serum levels of CRP. Although further investigations are needed to understand the exact mechanisms, our findings highlight immune response and metabolic regulatory pathways involved in the regulation of chronic inflammation, as well as several loci previously unknown to be related to inflammation. However, these single-nucleotide polymorphisms were not associated with incident myocardial infarction or coronary heart disease, either individually or in combination. A better knowledge of the molecular mechanisms that control serum CRP levels may lead to a deeper understanding of the complex interactions underlying the inflammatory response in cardiovascular disease.
Conclusions:
We identified 18 loci that were associated with CRP levels. Our study highlights immune response and metabolic regulatory pathways involved in the regulation of chronic inflammation. 9 
Genetic Risk Score and Risk of Myocardial Infarction in Hispanics
Summary: Coronary heart disease disproportionately affects certain ethnic groups. Hispanics are affected by excessive rates of cardiovascular risk factors such as diabetes mellitus, overweight and obesity, dyslipidemia, and hypertension. This study evaluated whether genetic markers identified from genome-wide association studies in whites were associated with myocardial infarction (MI) in Hispanics. We determined 14 variations in 1989 cases with a first nonfatal acute MI and 2096 population-based controls. Our results indicated that 7 single-nucleotide polymorphisms at 3 independent loci were associated with MI risk. A genetic risk score summing the number of the associated risk alleles was also associated with MI, per unit related to 18% (11%-25%) increased risk. The improvement in genetic markers on discrimination of MI, represented by the area under the receiver-operating characteristic curve, was modest but significant. Our findings highlight the importance of examining ethnic differences in genetic susceptibility to MI and indicate that consideration of multiple susceptibility signals may identify individuals with a markedly increased risk of MI.
Conclusions:
These results indicate both the consistency and disparity of genetic effects on risk of MI between Hispanic and white populations. The improvement in the identified genetic markers on discrimination of MI in Hispanics was modest. 10 
Identification of Genomic Predictors of Atrioventricular Conduction: Using Electronic Medical Records as a Tool for Genome Science
Summary: Three recent genome-wide association studies conducted in community populations have identified multiple loci contributing to variability in normal PR duration. This study sought to replicate these findings by performing a genome-wide association study in subjects identified in BioVU, the Vanderbilt DNA databank that accrues DNA from blood samples obtained during routine patient care and links these to a deidentified copy of the electronic medical record. Subjects were identified by combinations of natural language processing, laboratory queries, and billing code queries of medical record data. The genome-wide association study was conducted in 2334 European American patients with normal ECGs and no evidence of prior heart disease in the electronic medical record, and it confirmed a signal in a sodium channel gene, SCN10A, previously not implicated in cardiac pathophysiology as a modulator of PR interval in humans. This study is one of the first to validate use of an electronic medical records-derived cohort of genome-wide analysis, supporting their further use for genotype-phenotype analysis.
Conclusions: This genome-wide association study confirms a gene heretofore not implicated in cardiac pathophysiology as a modulator of PR interval in humans. This study is one of the first replication genome-wide association studies performed with the use of an electronic medical records-derived cohort, supporting their further use for genotype-phenotype analyses. 11
Independent Susceptibility Markers for Atrial Fibrillation on Chromosome 4q25
Summary: Atrial fibrillation (AF) is a heritable disorder with evidence of genetic susceptibility. Common single-nucleotide polymorphisms (SNPs) in a noncoding region on chromosome 4q25 have been associated with AF. We sought to determine whether more than 1 AF susceptibility signal exists at this locus. We genotyped SNPs at the chromosome 4q25 locus in 790 case subjects and 1177 control subjects. After adjustment for the genotype of the most significantly associated SNP, the SNPs that remained significantly associated with AF were replicated in an additional 5066 subjects with AF and 30 661 without AF. We identified 3 distinct AF susceptibility signals, 2 of which have not been described previously. A multimarker risk score composed of SNPs tagging each of these 3 AF susceptibility signals identified individuals at varying risk of developing AF. Among the 1% of subjects homozygous for AF risk alleles at SNPs tagging each susceptibility signal, the risk of AF was markedly increased relative to those with the most common genotypes at these SNPs (relative risk 6.02, 95% confidence interval 4.56 -7.96, Pϭ1.2ϫ10 Ϫ36 ). Consideration of multiple susceptibility signals at the chromosome 4q25 locus identifies individuals with a markedly increased risk of AF and may facilitate the localization of regulatory elements at this locus with particular biological relevance in the pathogenesis of AF.
Conclusions:
We identified 2 novel AF susceptibility signals on chromosome 4q25. Consideration of multiple susceptibility signals at chromosome 4q25 identifies individuals with an increased risk of AF and may localize regulatory elements at the locus with biological relevance in the pathogenesis of AF. 12 
Genetic Variation at the Phospholipid Transfer Protein Locus Affects Its Activity and High-Density Lipoprotein Size and Is a Novel Marker of Cardiovascular Disease Susceptibility
Summary: Whether modulation of high-density lipoprotein (HDL) metabolism will result in atheroprotection is one of the great conundrums of vascular medicine. Phospholipid transfer protein (PLTP) is a key player in HDL metabolism. The present study demonstrates a robust association between genetic variation in the PLTP gene, expression of PLTP in the liver, concentration and activity of PLTP in plasma, and cardiovascular disease risk, strengthening the concept that the actions of PLTP are proatherogenic in nature. Of note, PLTP genotype was not associated with HDL cholesterol concentrations but with HDL size distribution; apparently, PLTP action results in fewer but larger HDL particles. Together, these findings are consistent with the idea that specific elements of HDL metabolism may indeed affect cardiovascular risk but without necessarily affecting HDL cholesterol levels. More specifically, our observations suggest that the inhibition of PLTP may be an attractive strategy to reduce cardiovascular disease risk.
Conclusions:
A gene score based on 2 PLTP single nucleotide polymorphisms is associated with lower PLTP transcription and activity, an increased number of HDL particles, smaller HDL size, and decreased risk of cardiovascular disease. These findings indicate that PLTP is a proatherogenic entity and suggest that modulation of specific elements of HDL metabolism may offer cardiovascular benefit. 13 PLA2G7 Genotype, Lipoprotein-Associated Phospholipase A 2 Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624
Controls of European Ancestry
Summary: Lipoprotein-associated phospholipase A 2 (Lp-PLA2) is transported in the circulation on high-density lipoprotein and lowdensity lipoprotein cholesterol particles and is present in atheromatous plaques, where it may exert proatherogenic effects through generation of lysophosphatidylcholine and oxidized fatty acids. Higher Lp-PLA2 activity is associated with increased risk of coronary heart disease (CHD) in observational studies, making Lp-PLA2 a potential therapeutic target. However, higher Lp-PLA2 activity may simply mark alterations in blood lipids and other CHD risk factors, reflect (rather than contribute to) plaque, or even play an antiatherogenic role through the hydrolysis of the proinflammatory mediator platelet-activating factor and its analogues formed on oxidation of low-density lipoprotein cholesterol. We identified common variants of the PLA2G7 gene that encodes Lp-PLA2 associated with Lp-PLA2 activity and used these to clarify the nature of the association of Lp-PLA2 with other putative risk factors and CHD events using mendelian randomization. Genetic variants associated with modest effects on Lp-PLA2 activity were not associated with major alterations in cardiovascular risk factors, coronary atheroma, or CHD events. Larger mendelian randomization analyses, perhaps with the use of variants associated with larger effects on Lp-PLA2 activity, and randomized trials of specific Lp-PLA2 inhibitors will be needed to confirm or refute a contributory role for Lp-PLA2 in CHD.
Conclusions: Unlike Lp-PLA2 activity, PLA2G7 variants associated with modest effects on Lp-PLA2 activity were not associated with cardiovascular risk markers, coronary atheroma, or CHD. Larger association studies, identification of single-nucleotide polymorphisms with larger effects, or randomized trials of specific Lp-PLA2 inhibitors are needed to confirm or refute a contributory role for Lp-PLA2 in CHD. 14 
Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A
Summary: Homozygous or double heterozygous factor V Leiden and/or prothrombin G20210A is a rare inherited thrombophilic trait. Although individuals who have these mutations are at an Ϸ20-fold increased risk of first venous thrombosis, it is uncertain whether the risk of recurrence in these individuals is also increased. The clinical implications for such individuals, such as receiving anticoagulant treatment for an indefinite time after first venous thrombosis, depend on the risk of recurrence. In this case-control study, performed in a large cohort of thrombophilic families, we assessed the risk of recurrence of venous thrombosis in individuals with homozygosity or double heterozygosity for factor V Leiden and prothrombin G20210A. The cohort consisted of 788 individuals with prior venous thrombosis, of whom 325 had recurrent events. A total of 494 mutations were identified. Compared with noncarriers, carriers of the mutations factor V Leiden (nϭ283), prothrombin G20210A (nϭ82), double heterozygous (nϭ49) or homozygous factor V Leiden, or homozygous prothrombin G20210A (nϭ27) did not display an increased risk of recurrent events. Testing for these genetic mutations in patients with first venous thrombosis seems therefore to be of limited use.
Conclusions:
In this study, individuals with homozygous factor V Leiden and/or homozygous prothrombin G20210A or double heterozygous carriers of factor V Leiden and prothrombin G20210A did not have a high risk of recurrent venous thrombosis. 15 
Novel Associations of Multiple Genetic Loci With Plasma Levels of Factor VII, Factor VIII, and von Willebrand Factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium
Summary: Elevated circulating levels of coagulation factor VIII (FVIII) and von Willebrand factor (vWF) are risk factors for venous thrombosis, but the data supporting an association of coagulation factor VII (FVII) levels with arterial thrombosis are less consistent. Hemorrhagic complications are associated with deficiency in FVII and vWF (von Willebrand disease), as well as X-linked deficiency in FVIII (hemophilia A). To date, our understanding of genetic variation influencing plasma levels has been focused primarily on variation in the genes encoding each protein product (F7, F8, and VWF, respectively). Using data from 23 608 adults drawn from community populations, we investigated genome-wide associations between common genetic variation and plasma levels of FVII, FVIII, and vWF. For FVII, we identified 5 loci on 5 chromosomes that exceeded genome-wide significance. All loci were within or near genes, including 4 new candidate genes and F7. For vWF, we identified 8 loci on 6 chromosomes. All loci were within genes,
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Circulation September 11, 2012 including 6 new candidate genes, as well as ABO and VWF. For FVIII, 5 loci were identified and overlapped vWF findings. We replicated 9 of the 10 new findings in independent samples. In summary, new genetic associations were discovered in biological pathways not previously associated with circulating levels of these factors, including proteins implicated in uptake and intracellular transport of the factors. These findings may point to novel prevention and treatment targets of hemostasis disorders.
Conclusions: New genetic associations were discovered outside previously known biological pathways and may point to novel prevention and treatment targets of hemostasis disorders. 16 
Heterogeneity of Genetic Modifiers Ensures Normal Cardiac Development
Summary: Individuals who share the same underlying basis for congenital heart disease can have presentations ranging from normal to life-threatening. Understanding the basis of such wide variability could suggest prognostic and therapeutic strategies focused not on the causes but on the modifiers of disease. We thus characterized the effect of genetic modifiers on the incidence of heart defects associated with mutation of the cardiac transcription factor Nkx2-5.
Quantitative analyses of multiple inbred mouse strain crosses reveal the profound effect of polymorphic genetic modifiers. Protective and susceptibility alleles of modifier loci direct the manifestation of 1 or more types of heart defects, suggesting that they affect the sensitivity of specific cardiac developmental pathways to a perturbation. The modifiers alter the risk of a particular phenotype either independently or via epistatic interactions with other loci. The results intertwine the genetic basis of health and congenital heart disease, providing a conceptual framework to understand common clinical observations related to incomplete penetrance and pleiotropy. We propose that stabilizing selection generated a diverse set of polymorphisms so that in a genetically heterogeneous population the predominant effect of modifier genes is to ensure the robustness of cardiac development.
Conclusions:
Alleles of modifier genes can either buffer perturbations on cardiac development or direct the manifestation of a defect. In a genetically heterogeneous population, the predominant effect of modifier genes is health. 17
Targeted Next-Generation Sequencing for the Molecular Genetic Diagnostics of Cardiomyopathies
Summary: Proper genetic diagnosis of patients with primary heart muscle diseases, such as hypertrophic cardiomyopathy (HCM) or dilated cardiomyopathy (DCM), is paramount for individualized patient care, because some genetic forms are associated with disease manifestation at an early age, an overall poor prognosis, or a high incidence of sudden cardiac death. However, comprehensive genetic testing is not offered to all patients because of the genetic heterogeneity of cardiomyopathies as well as limitations in throughput and high costs of current genetic testing. Next-generation sequencing (NGS) technologies can generate gigabases of DNA sequence information in a single sequencing run, now fundamentally changing genomic research. In the present study, we report on the development of a comprehensive genetic testing strategy of patients with cardiomyopathy by an approach using microarray hybridization-based subgenomic enrichment of cardiomyopathy disease genes followed by SOLiD NGS in patients with HCM or DCM. 
PITX2 Insufficiency Leads to Atrial Electric and Structural Remodeling Linked to Arrhythmogenesis
Summary: Atrial fibrillation (AF) is the most frequent cardiac arrhythmia, leading to a high risk of mortality and morbidity. Though its prevalence is high, genetics of AF has remained rather elusive, with sporadic reports on point mutations in a wide variety of ion channel-encoding genes. Recently, genome-wide association studies have unraveled genetic variants (associated with AF risk) that are located close to the homeobox transcription factor PITX2 in a large proportion of AF patients. In the present investigation, we corroborated these findings in a small cohort of AF patients. We also provided evidence that PITX2 is downregulated in AF patients and experimentally demonstrated that Pitx2 insufficiency results in cellular and molecular changes leading to atrial electric and cellular remodeling linked to atrial arrythmogenesis. Thus, these findings provide insights into signaling pathways that are implicated in the pathogenesis of AF.
Conclusions: This study thus identifies PITX2 as an upstream transcriptional regulator of atrial electric function, the insufficiency of which results in cellular and molecular changes leading to atrial electric and structural remodeling linked to arrhythmogenesis. 20
Comparative Lipidomics Profiling of Human Atherosclerotic Plaques
Summary: Although lipids of human atherosclerotic plaques have been analyzed previously, target-focused measurements restricted to individual lipid classes remain insufficient to reveal the global lipid imbalances in atherosclerosis. We have adapted a liquid extractionbased surface sampling device for the analysis of plaque lipids from tissue sections. For quantitation, shotgun lipidomics was performed on lipid extracts using the different scan options of a triple quadrupole mass spectrometer. In total, 150 lipid species from 9 different classes were identified, of which 24 were detected in endarterectomies only. A comparison of 28 carotid endarterectomy specimens revealed lipid signatures of symptomatic-asymptomatic lesions as well as stable-unstable plaque areas. This comprehensive analysis of plaque lipids highlights the importance of measuring individual lipid species rather than lipid classes to obtain insights into the lipid heterogeneity within atherosclerotic lesions.
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Conclusions: This comprehensive analysis of plaque lipids demonstrates the potential of lipidomics for unraveling the lipid heterogeneity within atherosclerotic lesions. 21 
Dynamic MicroRNA Expression Programs During Cardiac Differentiation of Human Embryonic Stem Cells: Role for miR-499
Summary: The discovery and isolation of human embryonic stem cells (hESCs) have given medical science the tantalizing prospect of one day regenerating organs and tissues in human patients. This is because hESCs are pluripotent, which enables them to differentiate into virtually any cell type of the human body. However, forcing these cells to change their phenotype is an imperfect science and is often time-consuming, resource-intensive, and plagued by poor yields. Fundamentally, what is needed is better control over the factors that induce, maintain, and repress pluripotency and differentiation. MicroRNAs (miRNAs) are a newly discovered endogenous class of small RNAs that play important regulatory roles by targeting messenger RNAs for cleavage or translational repression. hESCs are known to express miRNAs that are often undetectable in adult organs, and a growing body of evidence has implicated miRNAs as important arbiters of heart development and disease. Here, we report the first miRNA profiling study of cardiomyocytes derived from hESCs and identify miRNAs, such as miR-499 and -1, that are strongly associated with cardiac differentiation. With the ultimate goal of discovering factors that might enhance cardiac differentiation, we then selected miR-499 and -1 for functional studies. Each miRNA had significant, though different, positive effects on cardiac differentiation, suggesting a powerful role for miRNAs in influencing hESC fate decisions. In the future, we believe miRNAs may play a key role in achieving higher yields of hESC-derived cardiomyocytes that can then be used for transplantation studies and, ultimately, clinical therapies.
Conclusions: Taken together, our data give significant insight into the regulatory networks that govern human embryonic stem cell differentiation and highlight the ability of miRNAs to perturb, and even control, the genes that are involved in cardiac specification of human embryonic stem cells. 22 The Importance of Genetic Counseling, DNA Diagnostics, and Cardiological Family Screening in Left Ventricular Noncompaction Cardiomyopathy Summary: In left ventricular (LV) noncompaction cardiomyopathy (LVNC), part of the LV wall is thickened and bilayered, consisting of a thick endocardial layer with prominent intertrabecular recesses and a thin, compact epicardial layer. To investigate the genetics of LVNC, we performed systematic family screening and extensive molecular testing of 58 consecutively diagnosed LVNC probands (49 adults and 9 children). This combined approach showed that 67% of LVNC is genetic in origin. In 64% of the probands, familial disease was demonstrated by screening 194 first-and second-degree relatives with electrocardiography and echocardiography. The majority (63%) of the relatives diagnosed with LVNC was asymptomatic, including 9 relatives with a mutation. Presymptomatic DNA testing also identified 8 unaffected (without the cardiac phenotype) carriers, explaining why many probands were initially unaware of familial disease. The molecular screening for mutations in 17 genes identified mutations in 11 genes in 41% of the probands (17 adults and 6 children). Most mutations were transmitted in an autosomal dominant mode. Two adults and 2 children were compound or double heterozygous for 2 different mutations. One adult proband had 3 mutations. In half of familial LVNC, the genetic defect remained inconclusive. These results show that LVNC is predominantly a genetic cardiomyopathy with variable clinical presentation ranging from asymptomatic to severe manifestations. Accordingly, the diagnosis of LVNC requires genetic counseling, DNA diagnostics, and echocardiographic family screening.
Conclusion: LVNC is predominantly a genetic cardiomyopathy with variable presentation ranging from asymptomatic to severe. Accordingly, the diagnosis of LVNC requires genetic counseling, DNA diagnostics, and cardiological family screening. 23 
Multiple Genetic Loci Influence Serum Urate Levels and Their Relationship With Gout and Cardiovascular Disease Risk Factors
Summary: Although the role of serum urate in the causal pathway for gout has been well characterized, substantial controversy exists regarding whether elevated serum urate also may be a cause of high blood pressure (BP), hyperglycemia, and chronic kidney disease; whether the association with serum urate observed in observational studies merely is a consequence of these conditions; or whether it is an artifact of uncontrolled confounding factors. Because the association between genes and disease generally is not subject to confounding by environmental factors or reverse causality, causal inferences between exposure and disease can be examined more specifically using Mendelian randomization. In the present investigation, we tested the association of a genetic score constructed using 8 loci associated with serum urate with coronary heart disease (CHD) and its risk factors, including gout, glucose, systolic BP, diastolic BP, estimated glomerular filtration rate, and chronic kidney disease. Except for gout, none of the associations was statistically significant, and the lack of associations was replicated in another equally large independent sample. Although further confirmation is warranted, our study helps to elucidate the relationship between serum urate and CHD and its risk factors, which may contribute to a better understanding of the usefulness of controlling serum urate for preventing and designing treatments for CHD and its risk factors.
Conclusions:
The genetic urate score analysis suggested a causal relationship between serum urate and gout but did not provide evidence for one between serum urate and cardiovascular risk factors and CHD. 24 
